title: Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.
abstract: Despite their opposite effects on signal transduction, the nonapeptide hormone arginine-vasopressin (AVP) and its V1a receptor-selective cyclic peptide antagonist d(CH2)5[Tyr(Me)2]AVP display homologous primary structures, differing only at residues 1 and 2. These structural similarities led us to hypothesize that both ligands could interact with the same binding pocket in the V1a receptor. To determine receptor residues responsible for discriminating binding of agonist and antagonist ligands, we performed site-directed mutagenesis of conserved aromatic and hydrophilic residues as well as nonconserved residues, all located in the transmembrane binding pocket of the V1a receptor. Mutation of aromatic residues of transmembrane region VI (W304, F307, F308) reduced affinity for the d(CH2)5[Tyr(Me)2]AVP and markedly decreased affinity for the unrelated strongly hydrophobic V1a-selective nonpeptide antagonist SR 49059. Replacement of these aromatic residues had no effect on AVP binding, but increased AVP-induced coupling efficacy of the receptor for its G protein. Mutating hydrophilic residues Q108, K128 and Q185 in transmembrane regions II, III and IV, respectively, led to a decrease in affinity for both agonists and antagonists. Finally, the nonconserved residues T333 and A334 in transmembrane region VII, controlled the V1a/V2 binding selectivity for both nonpeptide and cyclic peptide antagonists. Thus, because conserved aromatic residues of the V1a receptor binding pocket seem essential for antagonists and do not contribute at all to the binding of agonists, we propose that these residues differentiate agonist vs. antagonist ligand binding.
authors.affiliation: INSERM U469, Montpellier, France; CNRS UMR 5048, INSERM U414, CBS, Faculté de Pharmacie, Montpellier, France.
authors.forename: N
authors.initials: N
authors.lastname: Cotte
authors.forename: M N
authors.initials: MN
authors.lastname: Balestre
authors.forename: A
authors.initials: A
authors.lastname: Aumelas
authors.forename: E
authors.initials: E
authors.lastname: Mahé
authors.forename: S
authors.initials: S
authors.lastname: Phalipou
authors.forename: D
authors.initials: D
authors.lastname: Morin
authors.forename: M
authors.initials: M
authors.lastname: Hibert
authors.forename: M
authors.initials: M
authors.lastname: Manning
authors.forename: T
authors.initials: T
authors.lastname: Durroux
authors.forename: C
authors.initials: C
authors.lastname: Barberis
authors.forename: B
authors.initials: B
authors.lastname: Mouillac
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin / Q000378:metabolism; D001665:Binding Sites; D019556:COS Cells; D002462:Cell Membrane / Q000737:chemistry; D017124:Conserved Sequence; D006801:Humans; D008024:Ligands; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D017483:Receptors, Vasopressin / Q000737:chemistry* / Q000378:metabolism
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D008024:Ligands; D017483:Receptors, Vasopressin; D001127:Arginine Vasopressin